الفهرس 
anatomy of the breastOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
Currently, the clinical role of positron emission tomography (PET) and
PET/computed tomography (CT) in patients with breast cancer is to
provide additional information in select scenarios in which results of
conventional imaging are indeterminate or of limited utility. There is
currently no clinical role for fluorodeoxyglucose (FDG) PET in detection
of breast cancer or evaluation of axillary lymph nodes, but these are areas
of active research. FDG PET is complementary to conventional staging
procedures and should not be a replacement for either bone scintigraphy
or diagnostic CT. FDG PET and PET/CT have been shown to be
particularly useful in the restaging of breast cancer, in evaluation of
response to therapy, and as a problem-solving method when results of
conventional imaging are equivocal. In these situations, FDG PET often
demonstrates locoregional or unsuspected distant disease that affects
management. PET has demonstrated a particular capability for evaluation
of chemotherapy response in both patients with locally advanced breast
carcinoma and those with metastatic disease
Keyword breast cancer - PET/CT